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ZINARIA WILLIAMS LIU, AND ROBERT SEIBERT PURPOSE: To examine the time burden of managing
neovascular age-related macular degeneration (AMD)
imposed on physicians, staff, patients, and caregivers.
 DESIGN: Mixed-methods, prospective, observational
time-and-motion study.
 METHODS: The multicenter study was conducted from
March 2011 through August 2012. Retina specialists
administering ‡50 vascular endothelial growth factor
(VEGF)–inhibitor injections monthly were surveyed
and completed records for ‡5 patients scheduled for office
visits within 3 weeks for anti-VEGF injection or moni-
toring. A survey was administered to 75 neovascular
AMD patients aged ‡50 years who received ‡1 anti-
VEGF injection in the past 6 months. Telephone inter-
views were conducted with 13 neovascular AMD patient
caregivers.
 RESULTS: Fifty-six physicians provided data for 221
patients with neovascular AMD. Patients accounted for
20% of the health care staff’s time per week, with an
average of 23 staff members. An average patient visit
for neovascular AMDwas 90 minutes (range: 13 minutes
to>4 hours). Patients reported an average time per visit
of almost 12 hours, including preappointment prepara-
tion (16 minutes), travel (66 minutes), waiting time
(37 minutes), treatment time (43 minutes), and postap-
pointment recovery (9 hours). Patients stated that care-
givers took time away from work (22%) and personal
activities (28%) to provide transportation to appoint-
ments.
 CONCLUSIONS: Neovascular AMD management im-
poses a substantial time burden on physicians, staff, pa-
tients, and caregivers. There may be a need for
additional support and/or reimbursement for servicesr publication Jun 24, 2015.
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N
EOVASCULAR AGE-RELATED MACULAR DEGENER-
ation (AMD) is a debilitating, progressive disease
that has a profound impact on patients’ visual
acuity and overall visual function.1 It is the third-leading
cause of blindness worldwide, after cataracts and glaucoma,
and the leading cause of blindness in industrialized coun-
tries.1 It is estimated that 1.75 million individuals aged
>_40 years in the United States (US) (prevalence 1.47%;
95% confidence interval [CI] 1.38–1.55) have advanced
AMD, and an estimated 1.22 million (prevalence 1.02%;
95% CI 0.93–1.11) patients have neovascular AMD in at
least 1 eye; these numbers are expected to increase with
the aging population.2 As visual impairment progresses, in-
dependence and overall quality of life decline in parallel.3,4
As visual function declines, the negative impact on
activities of daily living substantially increases.5 This has
been shown to have a detrimental impact on cognitive
functioning, with 1 in 7 patients with AMD showing cogni-
tive decline.6 Patients with AMD have also shown an
increased risk of depression compared with patients
without AMD.7
As many as one-third of patients with AMD require
caregiving services owing to their AMD.8 As AMD pro-
gresses, these indirect costs for caregiver services form a
greater proportion of total costs,9 and caregiver burden
can be substantial.10
AMD also results in substantial economic impact in
terms of direct health care costs.8,9,11,12 Costs also
increase in direct proportion to disease progression.
Patients with AMD require more services (eg,
rehabilitation, counseling), devices, and supplements (eg,
approximately two-thirds of patients took vitamins with
lutein) than patients without AMD.9 Patients with neovas-
cular AMD incurred twice the annual costs per patient
compared to individuals without AMD (2011 US$: $34
308 vs $17 473), based on a cohort of 241 patients.11 Phy-
sicians must attempt to continually improve patient725LISHED BY ELSEVIER INC.
outcomes in the face of more stringent budgetary con-
straints, and health care decision makers (ie, physicians
and payers) struggle to balance quality of care with costs
of care and reimbursement for time and services provided.
The current mainstay of treatment for neovascular AMD
is anti–vascular endothelial growth factor agents (anti-
VEGFs), intravitreal therapeutics with demonstrated
efficacy in improving visual acuity in patients with neovas-
cular AMD.13–18 The management of patients with
neovascular AMD is costly and time consuming. The
provision of high-quality care requires commitments of sig-
nificant time and services from physicians, staff, patients,
and caregivers.
The objective of this multicenter, mixed-methods, pro-
spective, observational time-and-motion study was to un-
derstand the total physician and patient burden of the
current standard of care for management of neovascular
AMD in the US. This manuscript focuses on the quantita-
tive results from surveys of retina specialists, patients, and
associated patient records.METHODS
THIS MULTICENTER, MIXED-METHODS, PROSPECTIVE, OBSER-
vational time-and-motion study included 3 parts: (1) an
ethnographic study, (2) qualitative interviews of patients
with a diagnosis of neovascular AMD and their caregivers,
and (3) quantitative surveys of retina specialists and pa-
tients with a diagnosis of neovascular AMD. There was
no institutional review board (IRB) approval for the study,
as it was initially conducted (not by RTI Health Solutions)
as a market research project and patients were not
consented to have their records included in the study. After
conferring with the Journal, an exception to IRB approval
was permitted in order to have these nonidentifiable data
published.
Figure 1 presents an overall summary of the study.
First, an ethnographic study was conducted to gain a full
understanding of the intravitreal anti-VEGF treatment
process by means of observations and interviews conducted
during site visits to 10 retina specialists’ offices in the US.
This study consisted of 22 patients (17 established patients
receiving a possible reinjection of an anti-VEGF agent, and
5 new patients, receiving their first intravitreal injection of
an anti-VEGF agent). Four elements were included in the
ethnographic study design:
Patient shadowing: The observer shadowed the patient
throughout the entire visit to observe, record, and time
the activities that took place and to identify the staff
performing each activity. Waiting time that was not
directly associated with a particular procedure or test was
recorded separately. However, waiting time directly associ-
ated with a test was included into the average time for that
procedure.726 AMERICAN JOURNAL OFPostobservation debrief with health care provider staff to
collect information on office logistics and setting, standard
operating procedures, decision to administer anti-VEGF
therapy, steps in preparation and administration of anti-
VEGF therapy, postinjection examination and discharge,
delays in processing patients, challenges with current pro-
cess, and staff education and training.
Postobservation debrief with retina specialists to collect in-
formation on delays in processing patients, injection sched-
uling, consideration of comorbidities and well-being,
additional diagnostic procedures, use of as-needed vs
monthly injections, consideration of anti-VEGF alterna-
tives, and any limits on number of injections.
Postobservation debrief with office manager or the reimburse-
ment specialists to collect information on the mix of payers
involved, costs and reimbursement of diagnostic tests, re-
quirements for prior authorization, how anti-VEGF therapy
is obtained (ie, through the manufacturer/distributor or
through a specialty pharmacy), cost and reimbursement
for anti-VEGF therapy and the injection procedure, other
costs and reimbursement associated with the injection,
opinions on current process for anti-VEGF treatment,
and the impact of caregivers and disabilities on the process.
Qualitative research also was conducted through 1-hour
in-depth telephone interviews with 17 patients receiving
anti-VEGF treatment and 13 caregivers of patients with
neovascular AMD. A professional moderator trained in
techniques to build rapport and elicit deeper insights con-
ducted patient interviews. The aims were to assist in quan-
tifying the burden of care for neovascular AMD, identify
drivers and barriers to treatment, and understand the pa-
tient experience beyond the injection process in terms of
the impact on patient/caregiver quality of life and the
burden of time and effort involved. The results of this qual-
itative research helped in guiding the development of a
quantitative survey instrument.
Quantitative research followed, consisting of 3 elements.
The first was a telephone survey of 75 patients who had a
diagnosis of neovascular AMD, aged 50 years or older,
treated in the US by an ophthalmologist or retina
specialist, and who received at least 2 injections of anti-
VEGF treatment in the 6 months prior to the date of the
survey.
Secondly, a paper-based survey was issued to 57 retina
specialists in the US who had been recruited randomly
and then screened for eligibility until the quota was filled.
The recruiting, screening, and selection criteria followed
guidelines established by the Council of American Survey
Research Organizations. Eligibility criteria included the
requirement to have administered 50 or more anti-VEGF
inhibitor injections per month. The objective of this
portion of the research was to capture each step of an office
visit (including injection and monitoring) for the manage-
ment of neovascular AMD among patients who received
intravitreal injections of anti-VEGF agents. The specific
information captured concerned preparation required priorOCTOBER 2015OPHTHALMOLOGY
FIGURE 1. Overview of the study, which consisted of an ethnographic assessment, qualitative interviews of patients and their care-
givers, and quantitative surveys of retina specialists and patients. AMD[ age-related macular degeneration; VEGF[ vascular endo-
thelial growth factor.
TABLE.Number of Staff Members and Amount of TimeDedicated toManagement of Neovascular Age-RelatedMacular Degeneration
Staff Type
Average Number of Staff
Type Involved in Neovascular
AMD (Range)
Average Total % Time in a
40-Hour Work Week Spent in
Neovascular AMD Care (Range)
Average Time per Staff
Member per Week Spent
on Neovascular AMD
Average Hours per Week
Spent on Neovascular AMD,
All Staff Members
Receptionist 5 (1–18 people) 20% (1%–75%) 8 hours 28 hours
Office manager 2 (0–10 people) 13% (0%–75%) 4 hours 10 hours
Billing manager 2 (0–6 people) 22% (0%–80%) 8 hours 18 hours
Techniciana 8 (1–50 people) 34% (3%–90%) 14 hours 112 hours
Physicians other than
retina specialistsb
2 (0–18 people) 15% (0%–65%) 6 hours 12 hours
Other staff membersc 4 (1–12 people) 25% (5%–70%) 10 hours 40 hours
Total 23 people Average 20% of
individual’s work week
Average 10 hours of
individual’s work week
Total office time of
225 hours
AMD ¼ age-related macular degeneration.
aTechnician includes photographer, scribe, and lead technician.
bPhysicians other than retina specialists include residents, fellows, other ophthalmologists in the practice, or physician assistants.
cOther staff include medical assistants, optometrists, and nurse technicians.to patient arrival, time spent while the patient is in the of-
fice, and activities undertaken after the patient leaves, such
as reimbursement and billing.
The quantitative research section of this study was con-
ducted between July and November 2011; additional sam-
pling of respondents from Midwest and Great Plains states
was carried out from June through August 2012, as these re-
gions were underrepresented in the original sample. A total
of 20 states were sampled: Arizona, California, Colorado,
Connecticut, Florida, Georgia, Hawaii, Illinois, Iowa,
Missouri, Nebraska, New Jersey, New Hampshire, New
York, North Carolina, Ohio, Pennsylvania, South Dakota,
Texas, and Washington.VOL. 160, NO. 4 DISEASE BURDEN OF NEOVASCFinally, the same physicians also completed paper-based
forms for up to 5 neovascular AMD patients scheduled for
an office visit within the next 3 weeks (either for follow-up
evaluation or for treatment with an additional anti-VEGF
injection). The patients were required to be aged 50 years
and older and to have received at least 1 injection of
anti-VEGF therapy during the 6months prior to the survey.
The form included a patient history section for the physi-
cian to complete before the visit, and a patient diary in
which the physician recorded activities of the patient visit,
materials used, time taken for each step, and staff involve-
ment. The physicians were instructed to complete the pa-
tient diary on the same day as the patients’ visit.727ULAR AMD MANAGEMENT
> 60%
41% to 60%
21% to 40%
11% to 20%
0% to 10%
FIGURE 2. Average percentage of staff time involved with neovascular age-related macular degeneration. Number at the top of each
bar represents the average number of staff in that category involved in managing patients with neovascular age-related macular degen-
eration. Physicians other than retina specialists include residents, fellows, other ophthalmologists in the practice, or physician assis-
tants.RESULTS
THE PHYSICIANS WERE RANDOMLY RECRUITED FROM A
US-based list of retina specialists. Every physicianwho passed
screening for qualification agreed to participate. There were
57 retina specialists involved in the survey, 68% (39 of 57)
were in a group practice, 14% (8 of 57) practiced in an aca-
demic setting, and 18% (10 of 57) were solo practitioners.
The average total number of patients treated per month in
these 3 settings was 556, and the average number of neovas-
cular AMD patients treated per month was 201. Fifty-six of
the 57 retina specialists completed records on upcoming
visits, for a total of 221 patients with neovascular AMD.
The results of the retina specialist survey showed that on
average, 23 staff members were involved in the manage-
ment of neovascular AMD patients, including the recep-
tionist, the office manager, the billing manager,
technicians, and other physicians or staff (Table). The
management of patients with neovascular AMD accounted
for an average of 20% of the staff’s time per work week:
most technicians (68%) spent more than 20% of their
time, one-quarter of office managers spent more than
10% of their time, and more than one-third (37%) of
billing managers spent more than 20% of their time man-
aging patients with neovascular AMD (Figure 2).
Figure 3 summarizes the series of steps involved in the
management of a patient with neovascular AMD. Accord-
ing to the patient records, the time spent on 1 office visit by
a patient with neovascular AMD during 1 visit averaged728 AMERICAN JOURNAL OF90 minutes, but ranged from 13 minutes to over 4 hours.
The average time for new and established patients was
similar; however, how their timewas spent differed. New pa-
tients spentmore time with the technician during the initial
examination and with the photographer, and they had a
longer examination time with the retina specialist. Estab-
lished patients spent more of their clinic visit time waiting.
As shown in Figure 4, 8 preparatory steps were conducted
ahead of patient visits, with each step taking 4–8 minutes.
Although these preparatory steps were typically performed
concurrently, the average total staff time spent on all prep-
aration steps was 43 minutes.
When asked about the impact of activities for monitoring
and injection administration on staff time, the majority
of the surveyed retina specialists (62%, 35 of 57) felt that
frequency of patient monitoring placed a significant burden
on staff time. A large percentage of retina specialists (58%,
33 of 57) felt that billing and filing for reimbursement was
also a significant burden on staff resources. In addition,
42% (24 of 57) of retina specialists considered monitoring
frequency to be very impactful on material resources such
as drugs and other supplies. Forty-nine percent (28 of 57)
of retina specialists reported that the frequency of injections
was an impactful burden on office space, including waiting
rooms and examination rooms. Over one-third of physicians
(35%, 20 of 57) considered frequency of patient monitoring
to be an important motivator in choosing a treatment to
prescribe. Two-thirds of physicians (38 of 57) stated they
would find it very desirable to reduce office visits.OCTOBER 2015OPHTHALMOLOGY
FIGURE 3. Treatment of neovascular age-related macular degeneration: steps of patient flow and average times per step.A total of 75 patients were surveyed. The average age
was 79 years (range 55–98 years) and 89% (67 of 75) of
patients had a concomitant medical condition. The
average income was $40 000. The majority of patients
(62%, 46 of 75) reported an income of less than or equal
to $50 000. Seventeen percent (13 of 75) reported
an income between $50 001 and $75 000 while 10%
(8 of 75) had an income greater than $75 000. Eleven
percent (8 of 75) of patients chose not to answer this
survey question.
The patient survey elicited information on patient and
caregiver burden. Patients reported that the average time
commitment per visit for their neovascular AMD manage-
ment was 11.7 hours, including preappointment preparation
(16minutes), travel (66minutes), waiting time (37minutes),
treatment time (43 minutes), and an average of 9 hours of
postappointment recovery. More than one-third (36%, 27
of 75) of patients reported that their most recent visit took
90 minutes or more, and 79% (59 of 75) reported spending
at least 3 hours recovering following injections.
The majority of patients (72%, 54 of 75) were driven to
their appointment by a caregiver. Their caregiver was a
spouse or partner (65%, 35 of 54), an adult child or grand-
child (22%, 12 of 54), a friend (7%, 4 of 54), or another per-
son (6%, 3 of 54). Patients stated that the caregiver driving
them had to take time off from work (22%, 12 of 54) or per-
sonal activities (28%, 15 of 54) to accompany them to theirVOL. 160, NO. 4 DISEASE BURDEN OF NEOVASCappointment. Twenty percent (15 of 75) of patients drove
themselves, while 8% (6 of 75) took a car service or public
or government transportation.
Few patients experienced direct out-of-pocket transpor-
tation costs. Eighty-nine percent (67 of 75) reported that
they did not pay any transportation costs for their latest
clinic visit. Among those who had out-of-pocket transpor-
tation cost, 12% (8 of 67) paid for parking, 6% (4 of 67)
paid tolls, and 3% (2 of 67) paid bus fare.DISCUSSION
THIS ARTICLE PRESENTSACOMPREHENSIVE ASSESSMENTOF
the burden of managing patients with neovascular AMD in
the US. Previous studies have described the economic
burden of neovascular AMD8,9,11,12 but have not
specifically focused on the time and workforce burden
associated with the management of patients with the
disease. The present study demonstrated that practices
are highly invested in the management of patients with
neovascular AMD, with an average retina practice
consisting of 23 staff members involved in the disease
management for every 1 treating retina specialist.
Correspondingly, there is a substantial time commitment
required for each patient visit as a result of the numerous729ULAR AMD MANAGEMENT
FIGURE 4. Preparatory steps for neovascular age-related macular degeneration patients and average time. Question on retina specialist
survey was as follows: ‘‘In the following table, please identify the amount of time spent PREPARING for a typical Wet AMD patient
before the patient’s arrival. Indicate the activities done in preparation for eachWet AMD patient visit, including the person(s) involved
in the activity and the amount of time it takes to complete the activity (in minutes). If there is a PRE-PATIENT activity that is missing,
please write in the space provided at ‘‘OTHER.’’ EMR [ electronic medical record; ICG [ indocyanine green chorioangiography;
IVFA[ intravenous fluorescein angiography; OCT[ optical coherence tomography; VEFG[ vascular endothelial growth factor.steps and range of expertise involved. In total, the
management of patients with neovascular AMD accounts
for one-fifth of the staff’s working week, and this estimate
may likely underestimate the true workflow based on less
structured communications with retina specialists. In light
of pressures to reduce health care spending in the US,
devoting such time can be a challenging commitment in
a rapidly changing, cost-constrained environment while
trying to balance quality of care with costs.
In the current study, the majority of retina specialists felt
that injection frequency and the frequency of patient visits
placed a heavy burden on staff time; around half added that
it accounted for a disproportionate use of resources in terms
of materials and office space. As such, most physicians felt
that it would be very desirable to reduce injection frequency,
and almost half felt that it is an important motivator in pre-
scribing a particular treatment. It follows that a treatment
that requires fewer injections would be desirable, would be
more likely to be prescribed, and would ultimately reduce
the burden on health care staff time and the use of resources
such as materials and office space. Such reductions in physi-
cian and health care staff time and the overhead involved
in managing patients with neovascular AMDmay ultimately
lead to a reduction in theoverall burdenofneovascularAMD.
This study provides important neovascular AMD burden
information in the US; few time-and-motion studies have
been conducted in the area of neovascular AMD. One
other study, published in 1998, assessed time spent manag-
ing a range of ophthalmology conditions in the US,
including glaucoma, cataracts, myopia, macular edema,
and macular degeneration. The study did not separate mac-
ular degeneration into the dry and wet forms.19 The study
reported that an initial visit to a retina specialist for macu-
lar degeneration took around 25 minutes, with a follow-up730 AMERICAN JOURNAL OFvisit taking 40 minutes. These lengths of time were similar
to visits for other retinal conditions, but were shorter than
the visit times reported in our study. The increased time
committed to treating neovascular AMD is most likely
due to the fact that clinical evaluation, treatment options,
and health care coverage and management for patients
with AMD have changed significantly since 1998.
The strength of this study is its comprehensive methodol-
ogy, which includes both physician and patient perspectives
on neovascular AMD. It is based on responses of retina spe-
cialists from a wide variety of locations and practice types
around the US, and focuses on physicians who regularly
perform injection of anti-VEGF agents. However, selection
bias may have been present in terms of which physicians
chose to participate. These retina specialists may have
been more comfortable participating in clinical research
and therefore may not represent other segments of the retina
community accurately. Regarding patient enrollment, the
study includes a broad demographic range (50 years and
older) and range of income levels. The current study was a
US-only study; it may be useful to conduct similar studies
in other markets of interest. As with all similar survey
studies, the study is limited by the reliability of the physician
and patient responses, and by the potential for inaccurate
reporting of actual patient behavior and physician practices.
In conclusion, management of neovascular AMD carries
a substantial burden to patients, caregivers, physicians, and
their staff. The impact on staff time and health care
resources to diagnose, clinically evaluate, treat, and
schedule and process payments for patients with neovascu-
lar AMD equates to a significant commitment of resources.
Coupled with the quality-of-life burden to the patients and
their caregivers, the management of neovascular AMD has
a significant societal impact.OCTOBER 2015OPHTHALMOLOGY
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